Pretreatment KRAS-Mutant Circulating Tumor DNA Predicts Incidence and Patterns of Recurrence in Patients Undergoing Radiofrequency Ablation for Colorectal Liver Metastases: A Prospective Analysis - Pu
4 days ago
- #KRAS-mutant ctDNA
- #Radiofrequency Ablation
- #Colorectal Liver Metastasis
- Pretreatment KRAS-mutant circulating tumor DNA (ctDNA) predicts higher recurrence rates and shorter progression-free survival in colorectal liver metastasis (CRLM) patients undergoing radiofrequency ablation (RFA).
- Patients with KRAS-mutant ctDNA had a 71.4% recurrence rate compared to 31.6% in ctDNA-negative patients.
- Multivariate analysis identified >3 hepatic lesions and positive ctDNA status as independent predictors of recurrence.
- ctDNA-positive patients predominantly developed lung metastases (60%), while ctDNA-negative patients had liver-dominant recurrence (61.1%).
- Transcriptomic analysis linked ctDNA positivity to epithelial-mesenchymal transition and DNA repair pathways, with elevated nicotinamide N-methyltransferase expression correlating with aggressive phenotypes.